17/08/2021 Dacomitinib for treating EGFR mutation-positive non-small-cell lung cancer
The Ministry of Health’s Drug Advisory Committee has recommended:
- Dacomitinib 15 mg, 30 mg and 45 mg tablets for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer.
Subsidy status
RDacomitinib 15 mg, 30 mg and 45 mg tablets are recommended for inclusion on the MOH Standard Drug List (SDL) with effect from 3 August 2021.